...
首页> 外文期刊>Polish Archives of Internal Medicine >Presence of organ?specific antibodies in patients with systemic sclerosis
【24h】

Presence of organ?specific antibodies in patients with systemic sclerosis

机译:系统性硬化症患者器官特异性抗体的存在

获取原文
           

摘要

INTRODUCTION According to the literature, organ?specific antibodies may be present in the course of systemic sclerosis (SSc). OBJECTIVES The aim of this study was to assess the prevalence of antithyroid antibodies (antithyroid peroxidase antibodies [anti?TPO] and antithyroglobulin antibodies) and of antimitochondrial antibodies (AMAs), as well as to evaluate their clinical significance in patients with SSc. PATIENTS AND METHODS The study involved 86 consecutive in?hospital patients with SSc (32 patients with diffuse cutaneous SSc [dcSSc] and 54 with limited cutaneous SSc [lcSSc]). Patients were observed for autoimmune thyroid diseases (ATDs) and primary biliary cirrhosis (PBC). Serum samples were obtained from each patient. RESULTS Positive antithyroid antibody titers were observed in 27 patients (31%) and positive AMA titers—in 11 patients (13%). ATD was diagnosed in 26 patients (30%) and PBC—in 10 patients (12%) with SSc. No significant differences in the prevalence of antithyroid antibodies were found between patients with dcSSc and those with lcSSc, but the prevalence of AMAs was significantly higher in patients with lcSSc compared with those with dcSSc. The prevalence of anti?Ro?52 antibodies was significantly higher in the SSc group with positive anti?TPO antibody titers compared with the SSc group with negative anti?TPO antibody titers. The prevalence of anticentromere antibodies (ACAs) was significantly higher in the SSc group with positive AMA titers compared with the SSc group with negative AMA titers. CONCLUSIONS The prevalence of organ?specific antibodies in SSc patients is relatively high. The prevalence of AMAs is higher in patients with lcSSc than in those with dcSSc and is strongly associated with the presence of ACAs. Patients with SSc should be evaluated for coexisting ATDs and PBC.
机译:引言根据文献,在系统性硬化症(SSc)的过程中可能存在器官特异性抗体。目的本研究的目的是评估抗甲状腺抗体(抗甲状腺过氧化物酶抗体[anti?TPO]和抗甲状腺球蛋白抗体)和抗线粒体抗体(AMAs)的患病率,并评估其在SSc患者中的临床意义。患者与方法该研究纳入了86例连续住院的SSc患者(32例弥漫性皮肤SSc [dcSSc]和54例皮肤SSc [lcSSc])。观察患者的自身免疫性甲状腺疾病(ATD)和原发性胆汁性肝硬化(PBC)。从每位患者获得血清样品。结果在27例患者(31%)中观察到抗甲状腺抗体滴度为阳性,​​在11例患者(13%)中观察到AMA滴度为阳性。在26例SSc患者(30%)和PBC中诊断出了ATD,在10例SSc患者(12%)中诊断出了ATD。 dcSSc患者和lcSSc患者之间抗甲状腺抗体的患病率没有显着差异,但是lcSSc患者的AMAs患病率明显高于dcSSc患者。抗ΔTPO抗体滴度为阳性的SSc组中的抗αRoα52抗体的发生率比抗αTPO抗体滴度为阴性的SSc组的高。 AMA滴度为阳性的SSc组的抗着丝粒抗体(ACA)的发生率明显高于AMA滴度为阴性的SSc组。结论SSc患者中器官特异性抗体的患病率较高。 lcSSc患者的AMA患病率高于dcSSc患者,且与ACA的存在密切相关。 SSc患者应接受ATD和PBC并存的评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号